Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 218

GenFleet generates series B funding

Existing investor Sinopharm Capital came back for a $57.7m round that will support the progression of the small-molecule drug developer's pipeline.

Mar 12, 2020

Blackstone reaches HealthEdge for majority investment

Blackstone is paying an undisclosed amount for a majority share in the health plan management software provider, which raised $34m from Medica in 2017.

Mar 12, 2020

George Health gees up to raise $35m

George Health Enterprises and its subsidiary George Medicines have raised a combined $35m in funding from investors including Bupa Australia to drive pipeline development and commercialisation.

Mar 11, 2020

Corporates help LSP clasp $600m for new fund

Bristol Myers Squibb and Otsuka Pharmaceutical were among the limited partners for what LSP said is Europe's largest ever life sciences VC fund.

Mar 11, 2020

Silverback racks up series B funding

Bristol-Meyers Squibb participated in the $78.5m round, which will be used to push Silverback Therapeutics' lead cancer drug candidate towards clinical trials.

Mar 11, 2020

Numab makes room for series B funding

The cancer immunotherapy developer has closed a $23.6m round featuring 3SBio Group and Eisai, both of which have signed collaboration agreements with it in recent months.

Mar 11, 2020

RubiconMD gets the rub to raise $18m

Optum Ventures and Heritage Provider Network reinvested as the healthcare expertise platform increased its overall funding to $40m with a series C round led by Deerfield Managment.

Mar 11, 2020

InSightec locks in Koch for $150m series F

The ultrasound surgery system developer is targeting $150m at a $1.3bn post-money valuation, with Koch Disruptive Technologies supplying $100m.

Mar 10, 2020

Arkin makes a mark with $140m fund

Phoenix Group and Migdal have supplied capital for Arkin Bio-Ventures II, which investment firm Arkin Holdings will use to invest in 10 to 12 drug developers.

Mar 10, 2020

Zentalis enters IPO stage

The Pharmaron-backed cancer therapy developer is targeting $100m in an initial public offering preceded by $162m in funding.

Mar 10, 2020
© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here